CTOs on the Move

Affordable Quality Pharmaceuticals

www.aqpharmaceuticals.com

 
Affordable Quality Pharmaceuticals is a Garden Grove, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Arena Pharmaceuticals

We are a biopharmaceutical company focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver broad clinical utility across multiple therapeutic areas. Our proprietary pipeline includes potentially first- or best-in-class programs for which we own global commercial rights. Arena is headquartered in San Diego, CA, with operations in Boston, MA, and Zug, Switzerland.

Covis Pharma

Covis Pharma is a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses. Our paramount concern is patient`s outcomes as we focus on improving the health of people with serious medical conditions. Covis Pharma is a standalone company with global commercial, business development, product supply chain, product development, quality and regulatory functions based in Zug, Switzerland.

Nova-Tech Engineering Inc

Nova-Tech Engineering Inc is a Willmar, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Promius Pharma

Promius Pharma is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tobira Therapeutics

Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.